Stock BIVI BIOVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus BioVie Inc.

Equities

BIVI

US09074F2074

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
0.4884 USD +3.61% Intraday chart for BioVie Inc. -1.39% -61.24%
Mar. 11 BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities CI
Mar. 04 Top Midday Decliners MT

Evolution of the average Target Price on BioVie Inc.

Price target over the last 5 years

History of analyst recommendation changes

868.QpbTRQlNqRnEvOfwqoid7D_9V42VtpdJFSq8SGN_XY8.dNC3Jn8m0EywzJOG3-Go3luHYfuh5NoxfhP1JzNKOtUVxr0DcxLDVOnpkA~568176b835f927e9f283c6bc3a4f0d0a

Analyst Recommendations on BioVie Inc.

Oppenheimer Adjusts BioVie Price Target to $5 From $12, Maintains Outperform Rating MT
EF Hutton Adjusts Price Target for BioVie to $8 From $14, Maintains Buy Rating MT
B. Riley Lowers BioVie's Price Target to $12 from $18 Reflecting More Sharpened Focus of Target Model, Keeps Buy Rating MT
Cantor Fitzgerald Initiates BioVie at Overweight Rating With $7 Price Target MT
EF Hutton Adjusts BioVie's Price Target to $14 from $9, Keeps Buy Rating MT
Oppenheimer Starts BioVie at Outperform With $9 Price Target MT
B. Riley Lowers BioVie's Price Target to $18 from $27 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
B. Riley Lowers BioVie's PT to $27 from $50 to Reflect Continued Expansion in Research, Development Spend, Stretched Out Commercialization Timelines; Keeps Buy Rating MT
BIOVIE : B. Riley Raises BioVie's PT to $50 from $47 On Liver, Neurodegenerative, and Oncology Pipeline, Keeps Buy Rating MT
DJ Industrial : Stocks Fall Ahead of Fed Rate Decision MT
Midday Report: Wall Street Falls Ahead of Fed Rate Decision MT
BIOVIE : B. Riley Starts BioVie at Buy With $47 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.4884
Average target price
-

Consensus detail

Consensus revision (last 18 months)

Analysts covering BioVie Inc.

Oppenheimer
EF Hutton
B. Riley
Cantor Fitzgerald

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BIVI Stock
  4. Consensus BioVie Inc.